TGF-β-responsive CAR-T cells promote anti-tumor immune function

Area of Science:

• Immunology
• Cell Therapy
• Cancer Research

Background:

• Transforming growth factor beta (TGF-β) is an immunosuppressive cytokine often found in the tumor microenvironment.
• Chimeric antigen receptor (CAR) T-cell therapy shows promise for cancer treatment but faces challenges with immunosuppression.
• Engineering T cells to respond to TGF-β could convert its immunosuppressive function into a T-cell stimulant.

Purpose of the Study:

• To engineer T cells with TGF-β-responsive CARs for cancer therapy.
• To evaluate the ability of TGF-β CAR-T cells to enhance anti-tumor immunity.
• To assess the safety and efficacy of TGF-β CAR-T cells in mixed T-cell populations, particularly regarding regulatory T cells (Tregs).

Main Methods:

• Development of TGF-β-responsive CARs for T-cell engineering.
• Co-culture experiments with TGF-β CAR-T cells and tumor cells.
• Analysis of T-cell expansion, cytokine production, and anti-tumor activity in mixed T-cell populations.

Main Results:

• TGF-β CAR-T cells significantly enhanced the anti-tumor efficacy of neighboring cytotoxic T cells.
• Introduction of TGF-β CARs did not lead to preferential expansion of contaminating regulatory T (Treg) cells.
• TGF-β CAR-Treg cells did not mediate suppression of effector T (Teff) cells.

Conclusions:

• TGF-β CAR-T cells can convert an immunosuppressive cytokine into a T-cell stimulant, improving anti-tumor responses.
• The use of TGF-β CARs in mixed T-cell populations is safe and does not promote Treg-mediated suppression.
• TGF-β CAR technology holds potential for developing novel adoptive T-cell therapies for cancer.